Siga Technologies (NSDQ:SIGA) said today that data from a pivotal human safety study and animal efficacy studies of its oral smallpox therapy were published in the New England Journal of Medicine.
Data from the studies support the efficacy and favorable safety profile of Tpoxx, an oral formulation of tecovirimat.
Get the full story at our sister site, Drug Delivery Business News.
The post Siga Technologies touts pivotal data for oral smallpox therapy appeared first on MassDevice.